531 related articles for article (PubMed ID: 15824225)
21. Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis.
Parodi MB; Iacono P; Kontadakis DS; Zucchiatti I; Cascavilla ML; Bandello F
Arch Ophthalmol; 2010 Sep; 128(9):1100-3. PubMed ID: 20837791
[TBL] [Abstract][Full Text] [Related]
22. A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration.
Sivaprasad S; Patra S; DaCosta J; Adewoyin T; Shona O; Pearce E; Chong NV
Ophthalmologica; 2011; 225(4):200-6. PubMed ID: 21293163
[TBL] [Abstract][Full Text] [Related]
23. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.
Koh A; Lee WK; Chen LJ; Chen SJ; Hashad Y; Kim H; Lai TY; Pilz S; Ruamviboonsuk P; Tokaji E; Weisberger A; Lim TH
Retina; 2012 Sep; 32(8):1453-64. PubMed ID: 22426346
[TBL] [Abstract][Full Text] [Related]
24. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone.
Augustin AJ; Puls S; Offermann I
Retina; 2007 Feb; 27(2):133-40. PubMed ID: 17290193
[TBL] [Abstract][Full Text] [Related]
25. Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy, intravitreal dexamethasone, and intravitreal bevacizumab).
Ehmann D; García R
Can J Ophthalmol; 2010 Feb; 45(1):36-40. PubMed ID: 20130708
[TBL] [Abstract][Full Text] [Related]
26. Combination photodynamic therapy and intravitreal ranibizumab in neovascular AMD in a north Indian population: a pilot study.
Kumar A; Gopalakrishnan K; Sinha S
Retina; 2008 Oct; 28(8):1132-7. PubMed ID: 18779720
[TBL] [Abstract][Full Text] [Related]
27. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.
Kaiser PK; Boyer DS; Cruess AF; Slakter JS; Pilz S; Weisberger A;
Ophthalmology; 2012 May; 119(5):1001-10. PubMed ID: 22444829
[TBL] [Abstract][Full Text] [Related]
28. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.
Heier JS; Boyer DS; Ciulla TA; Ferrone PJ; Jumper JM; Gentile RC; Kotlovker D; Chung CY; Kim RY;
Arch Ophthalmol; 2006 Nov; 124(11):1532-42. PubMed ID: 17101999
[TBL] [Abstract][Full Text] [Related]
29. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2.
Renno RZ; Terada Y; Haddadin MJ; Michaud NA; Gragoudas ES; Miller JW
Arch Ophthalmol; 2004 Jul; 122(7):1002-11. PubMed ID: 15249365
[TBL] [Abstract][Full Text] [Related]
30. Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
Sato T; Kishi S; Matsumoto H; Mukai R
Am J Ophthalmol; 2013 Jul; 156(1):95-105.e1. PubMed ID: 23628354
[TBL] [Abstract][Full Text] [Related]
31. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
[TBL] [Abstract][Full Text] [Related]
32. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial.
Bressler NM; Chang TS; Fine JT; Dolan CM; Ward J;
Arch Ophthalmol; 2009 Jan; 127(1):13-21. PubMed ID: 19139332
[TBL] [Abstract][Full Text] [Related]
33. Prolongation of choroidal hypofluorescence following combined verteporfin photodynamic therapy and intravitreal triamcinolone acetonide injection.
Luttrull JK; Spink CJ
Retina; 2007; 27(6):688-92. PubMed ID: 17621176
[TBL] [Abstract][Full Text] [Related]
34. [Clinical trial of verteporfin photodynamic therapy in Chinese age-related macular degeneration with subfoveal predominant choroidal neovascularization patients].
Chen YX; Ge J; Yan M; Jin CJ; Zhang MX; Dong FT; Lu F; Zhang CF; Zhao JL
Zhonghua Yan Ke Za Zhi; 2007 Mar; 43(3):198-205. PubMed ID: 17605900
[TBL] [Abstract][Full Text] [Related]
35. Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials.
Barbazetto IA; Saroj N; Shapiro H; Wong P; Ho AC; Freund KB
Am J Ophthalmol; 2010 Jun; 149(6):939-946.e1. PubMed ID: 20378094
[TBL] [Abstract][Full Text] [Related]
36. Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography.
Hatta Y; Ishikawa K; Nishihara H; Ozawa S; Ito Y; Terasaki H
Retina; 2010 Mar; 30(3):495-502. PubMed ID: 19996828
[TBL] [Abstract][Full Text] [Related]
37. [Intravitreal ranibizumab in combination with verteporfin photodynamic therapy in neovascular macular degeneration].
Soucek P; Soucková I
Cesk Slov Oftalmol; 2008 Jul; 64(4):135-40. PubMed ID: 18780651
[TBL] [Abstract][Full Text] [Related]
38. [Photodynamic therapy with verteporfin combined with intravitreal injection of ranibizumab for occult and classic CNV in AMD].
Maier MM; Feucht N; Fiore B; Winkler von Mohrenfels C; Kook P; Fegert C; Lohmann C
Klin Monbl Augenheilkd; 2009 Jun; 226(6):496-502. PubMed ID: 19507101
[TBL] [Abstract][Full Text] [Related]
39. Combination therapy of intravitreal triamcinolone and photodynamic therapy with verteporfin for subfoveal choroidal neovascularization.
Hussain N; Das T; Rawal H; Kallukuri SB; Mohan Ram LS; Khanna R
Indian J Ophthalmol; 2006 Dec; 54(4):247-50. PubMed ID: 17090876
[TBL] [Abstract][Full Text] [Related]
40. Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin.
Schmidt-Erfurth UM; Michels S
Ophthalmology; 2003 Jul; 110(7):1306-14. PubMed ID: 12867383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
